CA2483005A1 - Treatment of metabolic syndrome - Google Patents

Treatment of metabolic syndrome Download PDF

Info

Publication number
CA2483005A1
CA2483005A1 CA002483005A CA2483005A CA2483005A1 CA 2483005 A1 CA2483005 A1 CA 2483005A1 CA 002483005 A CA002483005 A CA 002483005A CA 2483005 A CA2483005 A CA 2483005A CA 2483005 A1 CA2483005 A1 CA 2483005A1
Authority
CA
Canada
Prior art keywords
insulin
growth hormone
treatment
patients
sensitising agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002483005A
Other languages
English (en)
French (fr)
Inventor
Bernhard Saller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0209642A external-priority patent/GB0209642D0/en
Priority claimed from GB0218912A external-priority patent/GB0218912D0/en
Application filed by Individual filed Critical Individual
Publication of CA2483005A1 publication Critical patent/CA2483005A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
CA002483005A 2002-04-26 2003-04-24 Treatment of metabolic syndrome Abandoned CA2483005A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0209642A GB0209642D0 (en) 2002-04-26 2002-04-26 Metabolic syndrome
GB0209642.8 2002-04-26
GB0218912.4 2002-08-14
GB0218912A GB0218912D0 (en) 2002-08-14 2002-08-14 Metabolic syndrome
PCT/EP2003/004357 WO2003090784A1 (en) 2002-04-26 2003-04-24 Treatment of metabolic syndrome

Publications (1)

Publication Number Publication Date
CA2483005A1 true CA2483005A1 (en) 2003-11-06

Family

ID=29272006

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002483005A Abandoned CA2483005A1 (en) 2002-04-26 2003-04-24 Treatment of metabolic syndrome

Country Status (11)

Country Link
EP (1) EP1499357A1 (pt)
JP (1) JP2005523915A (pt)
KR (1) KR20040101545A (pt)
CN (1) CN1646167A (pt)
AU (1) AU2003227683A1 (pt)
BR (1) BR0309375A (pt)
CA (1) CA2483005A1 (pt)
IL (1) IL164670A0 (pt)
MX (1) MXPA04010544A (pt)
PL (1) PL372900A1 (pt)
WO (1) WO2003090784A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10231976B2 (en) * 2010-02-08 2019-03-19 Prairie Pharmaceuticals LLC Methods for the use of progestogen as a glucocorticoid sensitizer

Also Published As

Publication number Publication date
MXPA04010544A (es) 2005-08-16
JP2005523915A (ja) 2005-08-11
PL372900A1 (en) 2005-08-08
KR20040101545A (ko) 2004-12-02
BR0309375A (pt) 2005-03-29
AU2003227683A1 (en) 2003-11-10
WO2003090784A1 (en) 2003-11-06
CN1646167A (zh) 2005-07-27
EP1499357A1 (en) 2005-01-26
IL164670A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
Fogari et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes
Belli et al. Effect of rosiglitazone on insulin resistance, growth factors, and reproductive disturbances in women with polycystic ovary syndrome
Açbay et al. Can metformin reduce insulin resistance in polycystic ovary syndrome?
Mazziotti et al. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies
EP1928499B1 (en) Use of a dpp-iv inhibitor to reduce hypoglycemic events
Thompson et al. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin
Chapman et al. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus
Willi et al. Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin
van Thiel et al. Effects of dehydroepiandrostenedione, superimposed on growth hormone substitution, on quality of life and insulin-like growth factor I in patients with secondary adrenal insufficiency: a randomized, placebo-controlled, cross-over trial
Katoh et al. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy—a randomized controlled trial
CA2282467A1 (en) Preparations for the treatment of metabolic syndrome containing human growth hormone in combination with a cortisol synthesis inhibitor
AU2005297366A2 (en) GH secretagogues and uses thereof
Nagai et al. Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus
Akintoye et al. Pegvisomant for the treatment of gsp-mediated growth hormone excess in patients with McCune-Albright syndrome
CA1323575C (en) Use of bezafibrate for treating diabetes
Minnemann et al. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism
Herrmann et al. Effects of a combination of recombinant human growth hormone with metformin on glucose metabolism and body composition in patients with metabolic syndrome
Juhl et al. Repaglinide acutely amplifies pulsatile insulin secretion by augmentation of burst mass with no effect on burst frequency.
Theodor et al. Absolute bioavailability of moxonidine
CN104321074B (zh) 生长抑素类似物与11β‑羟化酶抑制剂的组合
AU2010257328A1 (en) Method of treatment using GH antagonist and somatostatin agonist
CA2483005A1 (en) Treatment of metabolic syndrome
Watts et al. Preliminary experience with a new stable isotope breath test for chylomicron remnant metabolism: A study in central obesity
ZA200408437B (en) Treatment of metabolic syndrome
Kutoh Differential regulations of lipid profiles between Japanese responders and nonresponders treated with pioglitazone

Legal Events

Date Code Title Description
FZDE Discontinued